Phone Number
(800) 210-7017
(800) 210-7017
Comparing kits well means treating them like three separate purchases stacked on top of each other, because biological quality, procedural ease, and total cost rarely move in the same direction. The kit that looks cheapest on the price sheet often isn’t, and the one with the slickest brochure isn’t always the one your knees and tendons actually want.
PRP kits in the orthopedic and pain space separate on platelet capture efficiency, concentration factor, leukocyte content, spin protocol, centrifuge dependency, and per-procedure all-in cost, with disposable prices running roughly one hundred to four hundred fifty dollars and concentration targets clustered between three and seven times baseline.
Strip away the glossy claims and the real comparison points are a short list of numbers any practice can ask the rep to produce on paper. If a manufacturer can’t give you yield percentage, concentration factor, RBC carryover, and batch coefficient of variation in writing, you don’t have enough to compare and you shouldn’t be signing anything.
A clinically credible PRP kit delivers 60% to 90% platelet capture, a 3x to 7x concentration factor, minimal red blood cell carryover, and under 15% batch-to-batch variance across healthy donors.
Kit architecture sets a ceiling on what you can get out of a draw, and that ceiling matters more than any marketing claim. Pushing concentration higher isn’t always better either, because platelet biology stops scaling linearly somewhere around five or six times baseline.
| Kit Architecture | Concentration Factor | Recovery Yield |
|---|---|---|
| Single-spin gel separator | 2x to 4x baseline | 50% to 70% |
| Double-spin manual | 4x to 7x baseline | Up to 80% in skilled hands |
| Closed-system high-concentration | 7x to 9x or higher | Tight, consistent batches |
Single-spin gel kits deliver 2x to 4x concentration with 50% to 70% yield, double-spin manuals reach 4x to 7x with yields up to 80%, and closed-system high-concentration kits push 7x to 9x or higher with the tightest batch consistency.
Ease of use is invisible on a Monday morning and decisive by Thursday afternoon when you’re running your fourth case of the day. The friction points stack up in small increments, and by month six they decide whether your staff still likes the kit or quietly resents it.
Single-spin gel-separator kits finish in 12 to 15 minutes with around five operator steps and one afternoon of training, while manual double-spin systems take 25 to 45 minutes, fifteen-plus steps, and several supervised runs before yields hold steady.
Disposable price tells you less than the per-procedure all-in, because accessories, anticoagulant, and activators ride along with every case. The cash-pay price you charge the patient runs five to ten times the disposable cost, which is what actually keeps the lights on.
Disposable pricing runs roughly one hundred to two hundred dollars for single-spin gel-separator kits, one hundred fifty to two hundred fifty for double-spin manuals plus ten to twenty in accessories, and two hundred fifty to four hundred fifty for closed-system high-concentration kits.
The FDA regulates the device that prepares the PRP, not the PRP itself, and that distinction is where most clinicians get the regulatory picture wrong. The cleared indication on a kit’s 510(k) varies more than the marketing makes it look, and the difference between “general blood handling” and “soft-tissue orthopedic injection” is a real liability gap.
Most PRP kits hold FDA 510(k) Class II clearance for general PRP preparation, only a small subset are cleared for orthopedic surgical use or specific soft-tissue indications, and CMS does not reimburse PRP for musculoskeletal applications under any clearance level.
The leukocyte question forces a real purchasing decision and most practices don’t realize they’re making one until the post-injection flare calls start coming in. The literature has settled enough that you can match the preparation to the indication without guessing.
| Dimension | Leukocyte-Rich (LR-PRP) | Leukocyte-Poor (LP-PRP) |
|---|---|---|
| Best fit | Tendinopathy, chronic tendon work | Knee osteoarthritis, intra-articular |
| Typical kit type | Single-spin gel separator | Double-spin manual or closed-system protocol |
| Post-injection flare | 24 to 72 hours of soreness, often pronounced | Lower flare risk in already-inflamed joints |
| Mechanism in play | Cytokine signaling from neutrophils and monocytes | Cleaner platelet-and-plasma preparation |
Leukocyte-rich PRP favors tendinopathy and chronic tendon injuries through inflammatory signaling, while leukocyte-poor PRP favors intra-articular knee osteoarthritis injections by avoiding the added flare that worsens an already inflamed joint.
Matching the kit to the practice is where most of the real money and clinical outcome gets decided, and the manufacturer’s rep almost never asks the three questions that matter. Case mix, monthly volume, and who’s actually preparing the kit on a given day are the variables that should drive the choice.
A practice should match kit choice to dominant case mix, monthly volume, and staff composition, with knee osteoarthritis practices favoring leukocyte-poor preparations, tendon-focused practices favoring leukocyte-rich, pain management defaulting to leukocyte-poor at moderate concentrations, and mixed practices stocking two kits because no single preparation serves both joint and tendon work well.
